Page 180 - Read Online

Harangi et al. HDL structure and function in dyslipidemia

Conflicts of interest Gemfibrozil increases paraoxonase activity in type 2 diabetic patients.
There are no conflicts of interest. A new hypothesis of the beneficial action of fibrates? Diabetes Metab
2001;27:604-10.
Patient consent 15. Nakou ES, Filippatos TD, Kiortsis DN, Derdemezis CS, Tselepis AD,
Mikhailidis DP, Elisaf MS. The effects of ezetimibe and orlistat, alone
Informed consent was obtained from all patients after or in combination, on high-density lipoprotein (HDL) subclasses and
approval of the local ethics committee. HDL-associated enzyme activities in overweight and obese patients
with hyperlipidaemia. Expert Opin Pharmacother 2008;9:3151-8.
Ethics approval 16. Harangi M, Seres I, Harangi J, Paragh G. Benefits and difficulties in
The study was approved by local and regional ethics measuring HDL subfractions and human paraoxonase-1 activity during
statin treatment. Cardiovasc Drugs Ther 2009;23:501-10.
committees. 17. Smolen A, Eckerson HW, Gan KN, Hailat N, La Du BN.
Characteristics of the genetically determined allozymic forms of human
serum paraoxonase/arylesterase. Drug Metab Dispos 1991;19:107-12.
REFERENCES 18. Schaefer EJ, Anthanont P, Asztalos BF. High-density lipoprotein
metabolism, composition, function, and deficiency. Curr Opin Lipidol
1. Hafiane A, Genest J. High density lipoproteins: Measurement 2014;25:194-9.
techniques and potential biomarkers of cardiovascular risk. BBA Clin 19. Li JJ, Zhang Y, Li S, Cui CJ, Zhu CG, Guo YL, Wu NQ, Xu RX, Liu
2015;3:175-88. G, Dong Q, Sun J. Large HDL subfraction but not HDL-C is closely
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen linked with risk factors, coronary severity and outcomes in a cohort of
M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study nontreated patients with stable coronary artery disease: a prospective
Investigators. Effect of potentially modifiable risk factors associated observational study. Medicine (Baltimore) 2016;95:e2600.
with myocardial infarction in 52 countries (the INTERHEART study): 20. Soran H, Schofield JD, Durrington PN. Antioxidant properties of HDL.
case-control study. Lancet 2004;364:937-52. Front Pharmacol 2015;6:222.
3. Ramirez A, Hu PP. Low high-density lipoprotein and risk of 21. Wang M, Lang X, Cui S, Zou L, Cao J, Wang S, Wu X. Quantitative
myocardial infarction. Clin Med Insights Cardiol 2015;9:113-7. assessment of the influence of paraoxonase 1 activity and coronary
4. Annema W, von Eckardstein A. Dysfunctional high-density heart disease risk. DNA Cell Biol 2012;31:975-82.
lipoproteins in coronary heart disease: implications for diagnostics and 22. Mackness B, Turkie W, Mackness M. Paraoxonase-1 (PON1) promoter
therapy. Transl Res 2016;173:30-57. region polymorphisms, serum PON1 status and coronary heart disease.
5. Huang Y, DiDonato JA, Levison BS, Schmitt D, Li L, Wu Y, Buffa J, Arch Med Sci 2013;9:8-13.
Kim T, Gerstenecker GS, Gu X, Kadiyala CS, Wang Z, Culley MK, 23. Hernández-Díaz Y, Tovilla-Zárate CA, Juárez-Rojop IE, González-
Hazen JE, Didonato AJ, Fu X, Berisha SZ, Peng D, Nguyen TT, Liang Castro TB, Rodríguez-Pérez C, López-Narváez ML, Rodríguez-Pérez
S, Chuang CC, Cho L, Plow EF, Fox PL, Gogonea V, Tang WH, JM, Cámara-Álvarez JF. Effects of paraoxonase 1 gene polymorphisms
Parks JS, Fisher EA, Smith JD, Hazen SL. An abundant dysfunctional on heart diseases: systematic review and meta-analysis of 64 case-
apolipoprotein A1 in human atheroma. Nat Med 2014;20:193-203. control studies. Medicine (Baltimore) 2016;95:e5298.
6. Khine HW, Teiber JF, Haley RW, Khera A, Ayers CR, Rohatgi A. 24. Zhou B, Zu L, Chen Y, Zheng X, Wang Y, Pan B, Dong M, Zhou E,
Association of the serum myeloperoxidase/high-density lipoprotein Zhao M, Zhang Y, Zheng L, Gao W. Myeloperoxidase-oxidized high
particle ratio and incident cardiovascular events in a multi-ethnic density lipoprotein impairs atherosclerotic plaque stability by inhibiting
population: observations from the dallas heart study. Atherosclerosis smooth muscle cell migration. Lipids Health Dis 2017;16:3.
2017;263:156-62. 25. Teng N, Maghzal GJ, Talib J, Rashid I, Lau AK, Stocker R. The
7. Mackness M, Mackness B. Human paraoxonase-1 (PON1): Gene roles of myeloperoxidase in coronary artery disease and its potential
structure and expression, promiscuous activities and multiple implication in plaque rupture. Redox Rep 2017;22:51-73.
physiological roles. Gene 2015;567:12-21. 26. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T,
8. Perła-Kaján J, Jakubowski H. Paraoxonase 1 and homocysteine Simoons ML, Hamm CW; CAPTURE Investigators. Myeloperoxidase
metabolism. Amino Acids 2012;43:1405-17. serum levels predict risk in patients with acute coronary syndromes.
9. Ben-David M, Elias M, Filippi JJ, Duñach E, Silman I, Sussman JL, Circulation 2003;108:1440-5.
Tawfik DS. Catalytic versatility and backups in enzyme active sites: 27. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles
the case of serum paraoxonase 1. J Mol Biol 2012;418:181-96. RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE,
10. Gugliucci A, Menini T. Paraoxonase 1 and HDL maturation. Clin Chim Hazen SL. Prognostic value of myeloperoxidase in patients with chest
Acta 2015;439:5-13. pain. N Engl J Med 2003;349:1595-604.
11. Huang Y, Wu Z, Riwanto M, Gao S, Levison BS, Gu X, Fu X, 28. Szentpéteri A, Zsíros N, Varga VE, Lőrincz H, Katkó M, Seres I, Fülöp
Wagner MA, Besler C, Gerstenecker G, Zhang R, Li XM, DiDonato P, Paragh G, Harangi M. Paraoxonase-1 and myeloperoxidase correlate
AJ, Gogonea V, Tang WH, Smith JD, Plow EF, Fox PL, Shih DM, with vascular biomarkers in overweight patients with newly diagnosed
Lusis AJ, Fisher EA, DiDonato JA, Landmesser U, Hazen SL. untreated hyperlipidaemia. Vasa 2017;46:370-6.
Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary 29. Zsíros N, Koncsos P, Lőrincz H, Seres I, Katkó M, Szentpéteri A,
complex. J Clin Invest 2013;123:3815-28. Varga VE, Fülöp P, Paragh G, Harangi M. Paraoxonase-1 arylesterase
12. Harangi M, Mirdamadi HZ, Seres I, Sztanek F, Molnár M, Kassai A, activity is an independent predictor of myeloperoxidase levels in
Derdák Z, Illyés L, Paragh G. Atorvastatin effect on the distribution of overweight patients with or without cardiovascular complications. Clin
high-density lipoprotein subfractions and human paraoxonase activity. Biochem 2016;49:862-7.
Transl Res 2009;153:190-8. 30. Haraguchi Y, Toh R, Hasokawa M, Nakajima H, Honjo T, Otsui K, Mori
13. Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on K, Miyamoto-Sasaki M, Shinohara M, Nishimura K, Ishida T, Hirata
paraoxonase-1 status: A systematic review and meta-analysis of 25 K. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of
clinical trials. Prog Lipid Res 2015;60:50-73. dysfunctional high-density lipoprotein and risk stratification in coronary
14. Balogh Z, Seres I, Harangi M, Kovács P, Kakuk G, Paragh G. artery disease. Atherosclerosis 2014;234:288-94.

Vessel Plus ¦ Volume 1 ¦ December 28, 2017 173